The PennZone

PHILADELPHIA, Nov. 9, 2023 ~ Suvoda LLC, a leading global clinical trial technology company, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.

The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.

More on The PennZone

• Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
• Kilmaine Saints to Anchor St. Patrick's Day Weekend with Live Album Recording at XL Live
• PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys
• Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
• Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep

Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."

Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."

More on The PennZone

• Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
• Smallville, Sailor Moon, Reno 911! Stars Added To FAN EXPO Philadelphia Lineup, May 29-31
• FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
• $2.7 Million 2025 Revenue; All Time Record Sales Growth; 6 Profitable Quarters for Homebuilding Industry: Innovative Designs (Stock Symbol: IVDN)
• Beyond Spots & Dots Commits $50,000 to Penn State University Communications Students

The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."

Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.

---

Show All News | Report Violation